|
Olympus Corporation is a medical technology company operating through two main business segments: Digestive Endoscopy Solutions and Surgical Intervention. The Digestive Endoscopy Solutions segment provides gastrointestinal endoscopes, endoscopic treatment instruments, and related medical services. The Surgical Intervention segment offers urological products, respiratory products, surgical endoscopes, energy devices, otolaryngology products, and gynecological products. Key subsidiaries include Olympus Medical Systems, Olympus Marketing, Olympus America Inc., Olympus Europa SE & Co. KG, Gyrus ACMI, Inc., and Swan EndoSurgical, Inc. The company serves global markets through regional entities in the Americas, Europe, Asia, and specific locations such as Beijing, Suzhou, Korea, Singapore, and Vietnam. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage olympus.co.jp |
| Sector Healthcare | IR page olympus.co.jp | |
|
Tags
endoscopy, surgical instruments, urology, respiratory care, energy devices, gynecology, otolaryngology, medical services, Olympus Medical Systems, Olympus Marketing, Aizu Olympus, Shirakawa Olympus, Nagano Olympus, Aomori Olympus, T-Medics, Olympus America Inc., Olympus Europa SE & Co. KG, Olympus Deutschland GmbH, KeyMed (Medical & Industrial Equipment) Ltd., Olympus Winter & Ibe GmbH, Olympus (Beijing) Sales & Service Co. Ltd., Olympus (Suzhou) Medical Device Co. Ltd., Olympus Korea Co. Ltd., Olympus Singapore Pte. Ltd., Olympus Vietnam Co. Ltd., Swan EndoSurgical Inc., Gyrus ACMI Inc., Sony Olympus Medical Solutions, Olympus Corporation of the Americas, Olympus Europa Holding SE, Olympus (China) Co. Ltd., Olympus Corporation of Asia Pacific Limited., Olympus Global Treasury Services Limited
|
Press page olympus.co.jp/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 2.259T |
| Market cap (USD) | $ 14.151B |
| P/E | 24.10 |
| PEG | — |
| P/BV | 2.99 |
| P/S | 2.12 |
| P/OCF | 15.92 |
| P/FCF | 35.43 |
| Dividend yield | 1.5% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 8.7% |
| ROI | 6.5% |
| ROIC | 6.7% |
| Profit margin | 6.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | -22.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 10 |
| Quality score | -5.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.011T | 997.332B | 936.21B | 881.923B | 868.867B | 730.544B | 797.411B | 793.862B | 788.996B | 748.05B | 804.578B | 764.671B | 713.286B | 743.851B |
| Net profit | 68.172B | 117.855B | 242.566B | 143.432B | 115.742B | 12.918B | 51.67B | 8.147B | 46.184B | 78.191B | 62.594B | -8.737B | 13.627B | 8.02B |
| Free cash flow | 18.162B | 125.254B | -22.259B | 50.92B | 107.958B | 64.895B | 67.615B | 5.477B | — | 42.944B | -7.788B | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 1.488K | 1.946K | 2.207K | 2.317K | 2.34K | 2.291K | 1.562K | 1.202K | 4.039K | 4.274K | 1.092K | 1.116K | 3.291K | 2.212K |
| Price performance 12m | -0.24 | -0.12 | -0.05 | -0.01 | 0.02 | 0.47 | 0.3 | -0.7 | -0.05 | 2.91 | -0.02 | -0.66 | 0.49 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 138B | 157B | 155B | 143B | 158B | 178B | 175B | 198B | 204B | 237B |
| ↳ YoY growth | -1.9% | -1.3% | -7.9% | +10.4% | +13.0% | -2.1% | +13.1% | +3.3% | +16.0% | |
| ↳ 5y CAGR | +2.1% | +4.9% | +7.4% | +8.4% | ||||||
| Borrowings, current (JPY) | 68.9B | 88.8B | 59.7B | 81B | 31.5B | 52.3B | 50B | 70B | 95B | 79.9B |
| Borrowings, non-current (JPY) | 218B | 159B | 122B | 200B | 324B | 334B | 290B | 230B | 134B | 160B |
| Bonds payable (JPY) | 25B | — | — | — | — | — | — | — | — | — |
| Cash and deposits (JPY) | 199B | 191B | 114B | 162B | 217B | 303B | 169B | 341B | 253B | 188B |
| Intangible assets (JPY) | 131B | 73.4B | 69.3B | 74.8B | 100B | 120B | 115B | 92B | 94B | 101B |
| Net debt (borrowings + leases - cash) (JPY) | 86.9B | 56.7B | 66.9B | 118B | 138B | 83.6B | 171B | -41.3B | -23.4B | 51.5B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 98.6B | 84.8B | 66.9B | 134B | 124B | 170B | 98.5B | 42.4B | 190B | 101B |
| Purchases of property, plant and equipment (JPY) | -43.5B | -48.9B | -47.1B | -37.8B | -38.7B | -41.7B | -47.6B | -46.4B | -46B | -55.6B |
| Purchases of intangible assets (JPY) | -3.71B | -14.6B | -14.4B | -28.2B | -20.6B | -20.1B | -23.1B | -18.2B | -19.2B | -26.9B |
| Change in receivables (cash effect) (JPY) | -660M | 1.73B | 5.58B | 1.28B | -9.72B | -11B | -27B | -11.9B | -27.7B | -30.5B |
| Change in inventories (cash effect) (JPY) | -14.8B | -13.2B | -14.4B | -16.4B | 4.02B | -2.1B | -26.9B | -19.1B | -3.41B | -10.7B |
| Change in payables (cash effect) (JPY) | 1.2B | -13.7B | 3.11B | 731M | 7.36B | -8.83B | 8.77B | -5.94B | -1.93B | 18.5B |
| Dividends paid (cash effect) (JPY) | -5.82B | -9.58B | -9.56B | -10.2B | -12.9B | -15.4B | -17.8B | -20.1B | -21B | -22.6B |
| Share buybacks (cash effect) (JPY) | -8M | -3.66B | -8M | -93.4B | -2M | -30B | -50B | -180B | -100B | -50B |
| Interest paid (cash effect) (JPY) | -7.65B | -6.38B | -4.62B | -3.69B | -3.36B | -4.29B | -5.39B | -4.8B | -4.19B | -4.05B |
| Income taxes paid (cash effect) (JPY) | -7.16B | — | — | — | — | — | — | — | — | — |
| Operating cash flow before change in receivables (JPY) | 90.9B | 93.4B | 61.4B | 132B | 134B | 181B | 126B | 54.2B | 218B | 131B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 42.9B | 31.7B | 5.48B | 67.6B | 64.9B | 108B | 27.9B | -22.3B | 125B | 18.2B |
| Income detail | ||||||||||
| Research and development expense (JPY) | 79.2B | — | 94B | 91.6B | 81.8B | 85.3B | 76.9B | 86.4B | 104B | 110B |
| ↳ 5y CAGR | -1.7% | +2.6% | +6.1% | |||||||
| Total comprehensive income (JPY) | 46.7B | 63.4B | 8B | 33.3B | 36.7B | 161B | 197B | 316B | 113B | 130B |
| Comprehensive income to owners (JPY) | 35B | 61.2B | 8.09B | 33.3B | 36.7B | 161B | 196B | 316B | 113B | 130B |
| Segments | ||||||||||
| Endoscopic Solutions · Segment operating income (JPY) | — | — | 89.8B | 109B | 105B | 133B | 153B | 105B | 141B | — |
| Gastrointestinal Solutions · Segment operating income (JPY) | — | — | — | — | — | — | — | — | 171B | 136B |
| Imaging · Segment operating income (JPY) | — | -1.2B | -18.3B | -10.4B | — | — | — | — | — | — |
| Medical · Segment operating income (JPY) | — | 122B | 112B | — | — | — | — | — | — | — |
| Scientific Solutions · Segment operating income (JPY) | — | 6.43B | 8.14B | 10B | 4.95B | 17.5B | — | — | — | — |
| Surgical And Interventional Solutions · Segment operating income (JPY) | — | — | — | — | — | — | — | — | 15.3B | -15B |
| Therapeutic Solutions · Segment operating income (JPY) | — | — | 22.2B | 26.2B | 24.6B | 60.8B | 63.7B | -8.47B | 61.5B | — |
| Reported | Jun 26, 2018 | Jun 25, 2019 | Jul 6, 2020 | Jul 6, 2020 | Jun 21, 2021 | Jun 21, 2022 | Jun 20, 2023 | Jun 20, 2024 | Jun 18, 2026 | Jun 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Olympus Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AIVI | 0.25% | 13,900 | $ 145.307K | Jun 30, 2026 |
| DIHP | 0.17% | 979,000 | $ 10.962M | Nov 12, 2026 |
| AVSD | 0.09% | 30,200 | $ 335.094K | Nov 16, 2026 |
| NTSI | 0.07% | 31,800 | $ 332.43K | Jun 30, 2026 |
| DFSI | 0.06% | 66,900 | $ 749.121K | Nov 12, 2026 |
| DFAI | 0.06% | 918,400 | $ 10.284M | Nov 12, 2026 |
| DXIV | 0.06% | 11,900 | $ 133.252K | Nov 12, 2026 |
| AVDE | 0.05% | 836,200 | $ 9.278M | Nov 16, 2026 |
| DFIC | 0.04% | 562,700 | $ 6.301M | Nov 12, 2026 |
| DFAX | 0.03% | 313,300 | $ 3.508M | Nov 12, 2026 |
オフィスやラボをオープン化し、人・情報の交流を促進
アクティビティごとに多様なワークスペースを配置
ENDOEYE FLEX 3D 先端湾曲ビデオスコープ OLYMPUS LTF-S700-10-3D
オリンパス公式Xアカウント 
オリンパス長野事業場の新「B棟」外観
(左から)新B棟とA棟
竣工式神事の様子
(写真左から)OEV-271MUH / OEV-321MUH / OEV-431MUH
左: 従来機種映り込みイメージ / 右: 反射・映り込み防止機能イメージ図